Pipeline

With our clinical and preclinical research programs we evaluate imlifidase across a wide spectrum of both potential disease areas and indications in an effort to address significant unmet medical needs.

Our broad pipeline spans pre-kidney transplantation desensitization, post-transplantation antibody-mediated organ rejection (AMR), rare IgG-mediated autoimmune conditions such as anti-glomerular basement membrane disease (anti-GBM), and Guillain-Barré Syndrome (GBS), as well as cancer. Full details on clinical program are available at: www.clinicaltrials.gov.

In preclinical development, we are also evaluating the use of imlifidase to potentially enable gene therapy treatment in patients with pre-existing neutralizing antibodies. Beyond imlifidase, we are developing our next generation IgG-cleaving enzyme program, NiceR, for repeat dosing. Finally, our EnzE program could potentially enhance the potency of oncology treatments.
Research

Broad pipeline in transplantation and autoimmune conditions

Interested in being involved?

If you are interested in getting involved in a clinical study, please talk to your physician. They will be able to advise you on whether you would be eligible to enroll into a study and if participation could be right for you.

Hansa Biopharma global access program policy

At this time, we are unable to offer access to unauthorized treatments via a compassionate use program that will provide an equitable and sustainable option for patients. However, we will evaluate and respond to each individual access request on a case-by-case basis. Clinicians considering suitability of their patients for access to clinical trials, can visit clinicaltrials.gov to see which Hansa trials are recruiting patients and where.